Genprex, Inc. Files 8-K Report
Ticker: GNPX · Form: 8-K · Filed: Jan 23, 2025 · CIK: 1595248
Sentiment: neutral
Topics: 8-K, SEC Filing, Other Events
Related Tickers: GNPX
TL;DR
Genprex filed an 8-K, but details are scarce. Watch for more info.
AI Summary
On January 23, 2025, Genprex, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific details regarding the nature of these events, any associated financial figures, or involved parties were provided in the excerpt.
Why It Matters
This 8-K filing signals that Genprex, Inc. has reported significant events to the SEC. Investors should monitor future filings for details on these events and their potential impact.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report with no immediate negative or positive financial implications disclosed in the provided text.
Key Players & Entities
- Genprex, Inc. (company) — Registrant
- January 23, 2025 (date) — Date of report
FAQ
What specific event(s) prompted this 8-K filing?
The provided text of the 8-K filing does not specify the nature of the 'Other Events' that prompted the report.
Are there any financial implications associated with the reported events?
The excerpt does not mention any specific dollar amounts or financial transactions related to the 'Other Events'.
When was this filing submitted to the SEC?
The filing was submitted on January 23, 2025.
What is Genprex, Inc.'s principal executive office address?
Genprex, Inc.'s principal executive offices are located at 3300 Bee Cave Road, #650-227, Austin, TX 78746.
What is Genprex, Inc.'s IRS Employer Identification Number?
Genprex, Inc.'s IRS Employer Identification Number is 90-0772347.
Filing Stats: 1,154 words · 5 min read · ~4 pages · Grade level 14 · Accepted 2025-01-23 08:00:15
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share GNPX The Nasdaq Capital M
Filing Documents
- gnpx20241220_8k.htm (8-K) — 34KB
- 0001437749-25-001630.txt ( ) — 165KB
- gnpx-20250123.xsd (EX-101.SCH) — 3KB
- gnpx-20250123_def.xml (EX-101.DEF) — 11KB
- gnpx-20250123_lab.xml (EX-101.LAB) — 15KB
- gnpx-20250123_pre.xml (EX-101.PRE) — 11KB
- gnpx20241220_8k_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On January 23, 2025, Genprex, Inc. ("Genprex" or the "Company") issued a press release in which it announced that the first patient has been enrolled and dosed in the Phase 2 expansion portion of the Company's Acclaim-3 clinical trial of Reqorsa Gene Therapy (quaratusugene ozeplasmid) in combination with Genentech's Tecentriq (atezolizumab) as maintenance therapy for patients with extensive stage small cell lung cancer ("ES-SCLC") who developed tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment. In December 2024, the Company previously announced that Genprex had completed the Phase 1 dose escalation portion of the trial and that the Safety Review Committee ("SRC") had approved the opening of the Phase 2 expansion portion of the trial. Based on full safety data, which showed no dose limiting toxicities, the SRC determined that the Recommended Phase 2 Dose of REQORSA will be 0.12 mg/kg. This was the highest dose level delivered in the Phase 1 portion of the trial. The Company anticipates that the Phase 2 expansion portion will enroll 50 patients at approximately 10 to 15 U.S sites. Patients will be treated with REQORSA and Tecentriq until disease progression or unacceptable toxicity is experienced. The primary endpoint of the Phase 2 portion is to determine the 18-week progression-free survival rate from the time of the start of maintenance therapy with REQORSA and Tecentriq in patients with ES-SCLC. Patients will also be followed for survival. A Phase 2 interim analysis will be performed after the 25th patient enrolled and treated reaches 18 weeks of follow up. The Company expects to complete enrollment of the first 25 patients for interim analysis in the Phase 2 expansion portion of the study in the second half of 2025. The Acclaim-3 clinical trial has received U.S. Food and Drug Administration ("FDA") Fast Track Designation for this patient population and Acclaim-3 has also received an FDA Orphan
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GENPREX, INC. Date: January 23, 2025 By: /s/ Ryan Confer Ryan Confer Chief Executive Officer and Chief Financial Officer (Principal Executive Officer and Principal Financial and Accounting Officer)